$10995 | Single User
$21990 | Site License
$32985 | Enterprise License

PharmaPoint: Allergic Rhinitis - Global Drug Forecast and Market Analysis to 2024
[Published by Global Data]

Published by Global Data: 01 Sep 2015 | 16986 | In Stock
Related Topics: Immunology

Introduction

PharmaPoint: Allergic Rhinitis - Global Drug Forecast and Market Analysis to 2024

Summary

Allergic Rhinitis (AR) is becoming an increasingly prevalent condition, with the most common form being moderate to severe in nature (Baena-Cagnani et al., 2015). According to the European Academy of Allergy and Clinical Immunology (EAACI), 50% of Europeans will suffer from an allergy by 2027 (Papadopoulos et al., 2012). The allergic rhinitis (AR) market has declined very slowly over the past decade, as has it become saturated with relatively efficacious standard therapies, such as antihistamines (AHs), intranasal corticosteroids (INCS), and leukotriene receptor antagonists (LRAs), and has also been facing increasing generic competition. Despite the rising prevalence of AR, and a large patient population that is dissatisfied with the current treatment options, the market size for symptomatic therapies alone is set to shrink, as the remaining branded products lose patent protection. There is an increasing shift in the transfer of prescription AR products to over-the-counter (OTC) status, which is driving patients to pharmacies rather than to physicians, further diluting the prescription AR market. The immense, crowded generic AR market has been largely unappealing to drug manufacturers. Consequently, only two symptomatic therapies are expected to launch before 2024.

Highlights

Key Questions Answered

- Allergic Rhinitis symptoms can be controlled in the majority of patients using the current standard therapies. Nevertheless, in around 20% of people with allergic rhinitis, the disease remains symptomatic and inadequately controlled. Therefore, there are considerably high unmet needs within the indication. What are the main unmet needs in this market?

- The current late-stage allergic rhinitis pipeline is sparse. Will the late-stage symptomatic drugs make a significant impact on the allergic rhinitis market? What strategies are drug developers undertaking to penetrate this difficult but potentially very lucrative market? How will immunotherapies affect the market landscape?

- The prevalence of environmental diseases, including allergic rhinitis, is increasing worldwide, with an estimated 46 million US citizens are likely to suffer from allergic rhinitis in 2024. How will epidemiological changes impact the growth of the future market?

Key Findings

- The main driver of growth in the AR market will be the introduction of several AIT tablets: Merck’s Grastek (grass), Ragwitek (ragweed), and Mitizax (house dust mite [HDM]) tablets, as well as Greer’s Oralair (grass) in the US. These new products overcome the inconvenience of conventional subcutaneous immunotherapies (SCITs).

- The major global barrier for the AR market will be the increasing push for patients to self-medicate using OTC drugs will decrease the prescription AR drug market size.

- There is little room for new entrants, as the market is well-served by a wealth of symptomatic therapies. Since the competition is increasing, the market for AR therapies is becoming increasingly less lucrative. Also, there are currently no breakthrough symptomatic therapy products in clinical development.

- The remaining clinical unmet needs in this market include the requirement for more efficacious products, and the underserved area of causative therapies, such as immunotherapies, which target the underlying cause of the disease.

Scope

- Overview of AR, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

- Annualized AR therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the AR therapeutics market.

- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

- Analysis of the current and future market competition in the global AR therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.

- Develop business strategies by understanding the trends shaping and driving the global AR therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AR therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Track drug sales in the global AR therapeutics market from 2014-2024.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents
for PharmaPoint: Allergic Rhinitis - Global Drug Forecast and Market Analysis to 2024 [Published by Global Data]

  • 1 Table of Contents

    1 Table of Contents 12

    1.1 List of Tables 18

    1.2 List of Figures 21

    2 Introduction 22

    2.1 Catalyst 22

    2.2 Related Reports 23

    2.3 Upcoming Related Reports 23

    3 Disease Overview 24

    3.1 Etiology and Pathophysiology 24

    3.2 Symptoms 27

    3.3 Classification 28

    3.3.1 Seasonal and Perennial AR 28

    3.3.2 ARIA Classification of AR 28

    3.4 Diagnosis 29

    3.5 Quality of Life 31

    4 Epidemiology 32

    4.1 Disease Background 32

    4.2 Risk Factors and Comorbidities 33

    4.2.1 A family history of AR is a strong predictor for AR in children and adults 34

    4.2.2 Exposure to allergens in the environment increases the risk for AR 35

    4.2.3 Urban living elevates the risk for AR 35

    4.2.4 Comorbidities 36

    4.3 Global and Historical Trends 38

    4.3.1 US 38

    4.3.2 5EU 39

    4.3.3 Japan 40

    4.4 Forecast Methodology 41

    4.4.1 Sources Used 43

    4.4.2 Sources Not Used 46

    4.4.3 Forecast Assumptions and Methods 46

    4.5 Epidemiological Forecast for AR (2013-2023) 49

    4.5.1 Total Prevalent Cases of AR 49

    4.5.2 Age-Specific Total Prevalent Cases of AR 51

    4.5.3 Sex-Specific Total Prevalent Cases of AR 53

    4.5.4 Age-Standardized Total Prevalence of AR 55

    4.5.5 Distribution of Total Prevalent Cases of AR by Severity 57

    4.5.6 Distribution of Total Prevalent Cases of AR by Type 58

    4.5.7 Distribution of Total Prevalent Cases of AR Sensitized to Specific Allergens 59

    4.6 Discussion 60

    4.6.1 Epidemiological Forecast Insight 60

    4.6.2 Limitations of the Analysis 60

    4.6.3 Strengths of the Analysis 61

    5 Disease Management 62

    5.1 Diagnosis and Treatment Overview 62

    5.1.1 Diagnosis 62

    5.1.2 Treatment Guidelines and Leading Prescribed Drugs 63

    5.1.3 Clinical Practice 66

    5.2 US 75

    5.3 France 78

    5.4 Germany 80

    5.5 Italy 84

    5.6 Spain 86

    5.7 UK 88

    5.8 Japan 90

    6 Competitive Assessment 93

    6.1 Overview 93

    6.2 Oral H1 Antihistamines 97

    6.2.1 Overview 97

    6.2.2 Efficacy 106

    6.2.3 Safety 107

    6.2.4 SWOT Analysis 109

    6.2.5 Forecast 110

    6.3 Intranasal Antihistamines 110

    6.4 Intranasal Corticosteroids 113

    6.4.1 Overview 113

    6.4.2 Efficacy 120

    6.4.3 Safety 122

    6.4.4 SWOT Analysis 123

    6.4.5 Forecast 124

    6.5 Combination Intranasal Corticosteroids/Antihistamines 124

    6.5.1 Dymista 124

    6.6 Decongestants 133

    6.6.1 Overview 133

    6.7 Intranasal Anticholinergics 136

    6.7.1 Overview 136

    6.8 Leukotriene Receptor Antagonists 137

    6.8.1 Overview 137

    6.9 Cromones 140

    6.9.1 Overview 140

    6.10 Thromboxane A2 Receptor Antagonists 141

    6.10.1 Overview 141

    6.11 TH2 Cytokine Inhibitors 142

    6.11.1 Overview 142

    7 Unmet Need and Opportunity 143

    7.1 Overview 143

    7.2 Pharmacist Education 145

    7.2.1 Unmet Need 145

    7.2.2 Gap Analysis 147

    7.2.3 Opportunity 148

    7.3 Patient Compliance With Intranasal Corticosteroids and Antihistamines 150

    7.3.1 Unmet Need 150

    7.3.2 Gap Analysis 151

    7.3.3 Opportunity 153

    7.4 More Convenient and More Patient-Friendly Immunotherapies 156

    7.4.1 Unmet Need 156

    7.4.2 Gap Analysis 157

    7.4.3 Opportunity 159

    7.5 Primary Care Physician Education 160

    7.5.1 Unmet Need 160

    7.5.2 Gap Analysis 162

    7.5.3 Opportunity 163

    8 Pipeline Assessment 165

    8.1 Promising Drugs in Clinical Development 166

    8.1.1 S-555739 166

    8.1.2 HP-3060 172

    9 Current and Future Players 177

    9.1 Overview 177

    9.2 Trends in Corporate Strategy 179

    9.3 Major Companies 180

    9.3.1 Merck & Co. 180

    9.3.2 GlaxoSmithKline 184

    9.3.3 Sumitomo Dainippon Pharma 186

    9.3.4 Sanofi 188

    9.3.5 Teva 191

    9.3.6 Meda AB 192

    10 Market Outlook 195

    10.1 Global Markets 195

    10.1.1 Forecast 195

    10.1.2 Drivers and Barriers - Global Issues 200

    10.2 United States 205

    10.2.1 Forecast 205

    10.2.2 Key Events 210

    10.2.3 Drivers and Barriers 210

    10.3 5EU 212

    10.3.1 Forecast 212

    10.3.2 Key Events 217

    10.3.3 Drivers and Barriers 217

    10.4 Japan 225

    10.4.1 Forecast 225

    10.4.2 Key Events 230

    10.4.3 Drivers and Barriers 230

    11 Appendix 234

    11.1 Bibliography 234

    11.2 Abbreviations 247

    11.3 Methodology 252

    11.4 Forecasting Methodology 252

    11.4.1 Pediatric Allergic Rhinitis Population 252

    11.4.2 Diagnosed AR Patients 258

    11.4.3 Percentage of Drug-Treated Patients 258

    11.4.4 Drugs Included in Each Therapeutic Class 258

    11.4.5 Launch and Patent Expiry Dates 261

    11.4.6 1General Pricing Assumptions 262

    11.4.7 Individual Drug Assumptions 263

    11.4.8 Generic Erosion 272

    11.4.9 Pricing of Pipeline Agents 272

    11.5 Physicians and Specialists Included in This Study 273

    11.6 About the Authors 277

    11.6.1 Analyst 277

    11.6.2 Therapy Area Director 277

    11.6.3 Epidemiologist 278

    11.6.4 Global Head of Healthcare 278

    11.7 About GlobalData 279

    11.8 Disclaimer 279

List Of Tables
in PharmaPoint: Allergic Rhinitis - Global Drug Forecast and Market Analysis to 2024 [Published by Global Data]

1.1 List of Tables

Table 1: Airborne Allergens That Cause AR 24

Table 2: Common Symptoms of AR 27

Table 3: Classification of AR Based on Etiological Type and Severity 33

Table 4: Common Risk Factors and Comorbidities for AR 34

Table 5: Prevalence of the Most Frequently Occurring Comorbidities in People with AR 37

Table 6: Age-Specific Prevalence of Hay Fever from the 2011 NHIS Survey 39

Table 7: Self-Reported Total Prevalence (%) of AR in the 5EU, Age 20-44 Years 39

Table 8: Total Prevalence (%) of AR in the EU, Age 6-14 Years 40

Table 9: 7MM, Sources of Data Used to Forecast the Total Prevalent Cases of AR 42

Table 10: 7MM, Sources Excluded from the Epidemiological Forecast for the Total Prevalent Cases of AR 46

Table 11: 7MM, Total Prevalent Cases of AR, Both Sexes, Ages ≥18 Years, N, 2013-2023 50

Table 12: 7MM, Age-Specific Total Prevalent Cases of AR, Both Sexes, N (Row %), 2013 52

Table 13: 7MM, Sex-Specific Total Prevalent Cases of AR, Ages ≥18 Years, N (Row %), 2013 54

Table 14: 7MM, Distribution of Total Prevalent Cases of AR by Severity, Both Sexes, N (Row %), 2013 57

Table 15: 7MM, Distribution of Total Prevalent Cases of AR by Type, Both Sexes, N (Row %), 2013 58

Table 16: 7MM, Proportion of Total Prevalent AR Cases Sensitized to Specific Allergens, Both Sexes, %, 2013 59

Table 17: Treatment Guidelines for AR 64

Table 18: Most Commonly Prescribed Drugs for AR in the 7MM by Class, 2014 65

Table 19: Major Brands of INCS 71

Table 20: Management of AR, Country Profile - US 77

Table 21: Management of AR, Country Profile - France 79

Table 22: Management of AR, Country Profile - Germany 83

Table 23: Management of AR, Country Profile - Italy 85

Table 24: Management of AR Country Profile - Spain 87

Table 25: Management of AR Country Profile - UK 89

Table 26: Management of AR, Country Profile - Japan 92

Table 27: Effects of Main Drug Classes on AR Symptoms 95

Table 28: Leading Branded Drugs Used to Treat AR, 2014 97

Table 29: Major Brands of Second- and Third-Generation Non-Sedating AHs 103

Table 30: Product Profile - AHs 106

Table 31: Efficacy of Bilastine in Symptomatic SAR Patients Age 12-70 Years 107

Table 32: Safety of Bilastine in Symptomatic SAR Patients Age 12-70 Years 108

Table 33: Oral AHs SWOT Analysis, 2014 109

Table 34: Global Sales Forecasts ($m) for Oral AHs, 2014-2024 110

Table 35: Major Brands of Intranasal Ahs 112

Table 36: Major Brands of INCS 118

Table 37: Product Profile - INCS 120

Table 38: Efficacy of FP ANS and BDP ANS in AR Patients Age 18-72 Years 121

Table 39: Safety Profile of FP ANS and BDP ANS in AR Patients Age 18-72 Years 122

Table 40: INCS SWOT Analysis, 2014 123

Table 41: Global Sales Forecasts ($m) for INCS, 2014-2024 124

Table 42: Product Profile - Dymista 129

Table 43: Efficacy of Dymista 130

Table 44: Safety of Dymista 131

Table 45: Dymista SWOT Analysis, 2014 132

Table 46: Global Sales Forecasts ($m) for Dymista, 2014-2024 133

Table 47: Unmet Need and Opportunity in AR 144

Table 48: Late-Stage Pipeline for AR, 2014 166

Table 49: Product Profile - S-555739 167

Table 50: Completed Clinical Trials of S-555739 in AR Patients 169

Table 51: S-555739 SWOT Analysis, 2014 171

Table 52: Global Sales Forecasts ($) for S-555739, 2014-2024 172

Table 53: Product Profile - HP-3060 173

Table 54: HP-3060 SWOT Analysis, 2014 175

Table 55: Global Sales Forecasts ($) for HP-3060, 2014-2024 176

Table 56: Major Companies in the AR Market and Their Portfolios, 2014 178

Table 57: Merck’s AR Portfolio Assessment, 2014 183

Table 58: GSK’s AR Portfolio Assessment, 2014 185

Table 59: Sumitomo Dainippon Pharma’s AR Portfolio Assessment, 2014 187

Table 60: Sanofi’s AR Portfolio Assessment, 2014 190

Table 61: Teva’s AR Portfolio Assessment, 2014 191

Table 62: Meda’s AR Portfolio Assessment, 2014 194

Table 63: Global Sales Forecasts ($m) for AR, 2014-2024 197

Table 64: Global AR Market - Drivers and Barriers, 2014-2024 200

Table 65: Sales Forecasts ($m) for AR in the US, 2014-2024 208

Table 66: Key Events Impacting Sales for AR in the US, 2014-2024 210

Table 67: AR Market - Drivers and Barriers in the US, 2014-2024 210

Table 68: Sales Forecasts ($m) for AR in the 5EU, 2014-2024 215

Table 69: Key Events Impacting Sales for AR in the 5EU, 2014-2024 217

Table 70: AR Market - Drivers and Barriers in the 5EU, 2014 217

Table 71: Sales Forecasts ($) for AR in Japan, 2014-2024 228

Table 72: Key Events Impacting Sales for AR in Japan, 2014-2024 230

Table 73: AR Market - Drivers and Barriers in Japan, 2014-2024 230

Table 74: Abbreviations 247

Table 75: Key Launch Dates of the Currently Available AR Therapies 261

Table 76: Key Loss of Exclusivity Dates of the Currently Available AR Therapies 262

Table 77: High-Prescribing Physicians (non-KOLs) Surveyed, by Country 276

List Of Figures, Charts and Diagrams
in PharmaPoint: Allergic Rhinitis - Global Drug Forecast and Market Analysis to 2024 [Published by Global Data]

1.2 List of Figures

Figure 1: Immunological Mechanisms Involved in the Early- and Late-Phase Allergic Response 26

Figure 2: ARIA Classification of AR by Duration of Symptoms and Severity 29

Figure 3: 7MM, Total Prevalent Cases of AR, Both Sexes, Age ≥18 Years, N, 2013-2023 51

Figure 4: 7MM, Age-Specific Total Prevalent Cases of AR, Both Sexes, N, 2013 53

Figure 5: 7MM, Sex-Specific Total Prevalent Cases of AR, Ages ≥18 Years, N, 2013 55

Figure 6: 7MM, Age-Standardized Total Prevalence (%) of AR, Ages ≥18 Years, by Sex, 2013 56

Figure 7: Algorithm Used for the Management of AR in the 7MM* 68

Figure 8: Company Portfolio Gap Analysis in AR, 2014-2024 179

Figure 9: Global Sales for AR by Region, 2014-2024 199

Figure 10: Sales for AR in the US by Drug Class, 2014-2024 209

Figure 11: Sales for AR in the 5EU by Drug Class, 2014-2024 216

Figure 12: Sales for AR in Japan by Drug Class, 2014-2024 229

Additional Details

Publisher

Global Data

Publisher Information

Reference

16986 | GDHC113PIDR

Number of Pages

280

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2025
PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2025SummaryGlobalData estim...
01 May 2016 by Global Data USD $10,995 More Info
PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023
PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023SummaryRenal cel...
21 Apr 2016 by Global Data USD $10,995 More Info
PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024SummaryPsoriasis (PsO) is a...
13 Apr 2016 by Global Data USD $10,995 More Info
PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024SummaryBipolar disor...
01 Mar 2016 by Global Data USD $10,995 More Info
PharmaPoint: Hepatitis B Virus (HBV) Therapeutics - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Hepatitis B Virus (HBV) Therapeutics - Global Drug Forecast and Market Analysis to 2024...
01 Jan 2016 by Global Data USD $10,995 More Info
PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024
PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024SummaryDry Eye Syn...
05 Nov 2015 by Global Data USD $10,995 More Info
PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2024SummaryAlthough the...
03 Nov 2015 by Global Data USD $10,995 More Info
PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023
PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023SummaryThe Multiple ...
01 Nov 2015 by Global Data USD $10,995 More Info
PharmaPoint: Peripheral Artery Disease - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Peripheral Artery Disease - Global Drug Forecast and Market Analysis to 2024SummaryIn t...
01 Oct 2015 by Global Data USD $10,995 More Info
PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024SummaryMultiple Sc...
10 Sep 2015 by Global Data USD $10,995 More Info

This report is published by Global Data

Download Free Report Summary PDF

PharmaPoint: Allergic Rhinitis - Global Drug Forecast and Market Analysis to 2024 [Published by Global Data] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...